Avidity Biosciences Inc

詳細情報 Avidity Biosciences Inc 企業名

Avidity Biosciences, Inc. is a biopharmaceutical company. The Company is engaged in delivering a new class of ribonucleic acid (RNA) therapeutics called antibody oligonucleotide conjugates (AOCs). The AOCs are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Its advancing and expanding pipeline has three programs in clinical development. AOC 1001 is designed to treat people with myotonic dystrophy type 1 (DM1) and is in phase I/II development with the ongoing MARINA open label extension study (MARINA-OLE). AOC 1044 is designed for people with Duchenne muscular dystrophy and is in phase I/II development with the EXPLORE44 trial. AOC 1020 is designed to treat people living with facioscapulohumeral muscular dystrophy (FSHD) and is in Phase I/II development with the FORTITUDE trial.

企業情報

企業コードRNA

会社名Avidity Biosciences Inc

上場日Jun 12, 2020

最高経営責任者「CEO」Ms. Sarah Boyce

従業員数391

証券種類Ordinary Share

決算期末Jun 12

本社所在地10578 Science Center Drive

都市SAN DIEGO

証券取引所NASDAQ Global Market Consolidated

国United States of America

郵便番号92121

電話番号18584017900

ウェブサイトhttps://www.aviditybiosciences.com/

企業コードRNA

上場日Jun 12, 2020

最高経営責任者「CEO」Ms. Sarah Boyce

役員一覧

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Sarah Boyce

President, Chief Executive Officer, Director

423.43K

+105.68%

Ms. Teresa Mccarthy

Chief Human Resources Officer

98.09K

+0.99%

Mr. John B. Moriarty

Chief Legal Officer, Corporate Secretary

50.00K

+100.00%

Ms. Kathleen P. Gallagher

Chief Program Officer

49.64K

-1.80%

Ms. Tamar Thompson

Independent Director

6.69K

--

Ms. Simona Skerjanec, M.D.

Independent Director

6.69K

--

Mr. Carsten Boess

Independent Director

6.69K

--

Dr. Edward M. (Ed) Kaye, M.D.

Independent Director

6.69K

--

Dr. W. Michael Flanagan, Ph.D.

Chief Scientific Officer

--

Mr. Eric B. Mosbrooker

Chief Commercial Officer

--

詳細を見る

会社名

会社名/ポジション

ポジション

株式保有

変動額

Ms. Sarah Boyce

President, Chief Executive Officer, Director

423.43K

+105.68%

Ms. Teresa Mccarthy

Chief Human Resources Officer

98.09K

+0.99%

Mr. John B. Moriarty

Chief Legal Officer, Corporate Secretary

50.00K

+100.00%

Ms. Kathleen P. Gallagher

Chief Program Officer

49.64K

-1.80%

Ms. Tamar Thompson

Independent Director

6.69K

--

Ms. Simona Skerjanec, M.D.

Independent Director

6.69K

--

収益内訳

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

データなし

地域別USD

会社名

収益

比率

United States

1.57M

0.00%

事業別

地域別

データなし

株主

更新時刻: Sat, May 17

株主統計

種類

株主統計

比率

Fidelity Management & Research Company LLC

12.69%

Janus Henderson Investors

9.48%

T. Rowe Price Associates, Inc.

9.30%

Wellington Management Company, LLP

8.03%

The Vanguard Group, Inc.

7.65%

Other

52.85%

株主統計

比率

Fidelity Management & Research Company LLC

12.69%

Janus Henderson Investors

9.48%

T. Rowe Price Associates, Inc.

9.30%

Wellington Management Company, LLP

8.03%

The Vanguard Group, Inc.

7.65%

Other

52.85%

種類

株主統計

比率

Investment Advisor/Hedge Fund

47.08%

Investment Advisor

46.95%

Hedge Fund

6.31%

Venture Capital

5.98%

Corporation

4.21%

Research Firm

2.59%

Private Equity

1.94%

Individual Investor

1.01%

Sovereign Wealth Fund

0.60%

機関投資家保有株

更新時刻: Tue, Jul 1

報告期間

機関投資家数

保有株式数

比率

変動額

2025Q2

495

141.64M

117.51%

-2.91M

2025Q1

508

142.16M

117.97%

-7.67M

2024Q4

492

135.01M

112.33%

-12.86M

2024Q3

467

132.62M

112.76%

+3.34M

2024Q2

414

118.94M

111.18%

+14.23M

2024Q1

365

96.48M

102.78%

+1.47M

2023Q4

345

83.09M

112.13%

-13.56M

2023Q3

334

86.17M

118.19%

-15.24M

2023Q2

328

86.81M

124.27%

-3.56M

2023Q1

328

80.46M

115.95%

-5.12M

詳細を見る

株主動向

会社名

保有株式数

比率

変動額

変動率

日付

Fidelity Management & Research Company LLC

15.29M

12.69%

-866.01K

-5.36%

Mar 31, 2025

Janus Henderson Investors

11.43M

9.48%

+4.37M

+62.01%

Mar 31, 2025

T. Rowe Price Associates, Inc.

11.21M

9.3%

+289.32K

+2.65%

Mar 31, 2025

Wellington Management Company, LLP

9.68M

8.03%

+1.58M

+19.47%

Mar 31, 2025

The Vanguard Group, Inc.

9.22M

7.65%

-188.71K

-2.01%

Mar 31, 2025

RTW Investments L.P.

8.75M

7.26%

+814.06K

+10.26%

Mar 31, 2025

BlackRock Institutional Trust Company, N.A.

8.40M

6.96%

-22.20K

-0.26%

Mar 31, 2025

Avoro Capital Advisors LLC

7.63M

6.33%

+125.00K

+1.67%

Mar 31, 2025

RA Capital Management, LP

6.30M

5.23%

--

Mar 31, 2025

Bristol Myers Squibb

5.08M

4.21%

--

Sep 30, 2024

詳細を見る

37.290USD

Avidity Biosciences Inc

37.290

概要

企業名

金融